ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0243

Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain

Carmen Lasa Teja1, Laura Muñoz-Llopis2, Diana Prieto-Peña3, Isla Morante Bolado4, José Luis Martín-Varillas5, Nerea Paz-Gandiaga6 and Ricardo Blanco7, 1Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, 4Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, 5Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, 6Rheumatology, Hospital Comarcal de Laredo, Laredo, Spain., Santander, 7Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

Meeting: ACR Convergence 2025

Keywords: Autoinflammatory diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic autoinflammatory diseases (SAIDs) are rare disorders characterized by recurrent episodes of fever, serositis, gastrointestinal symptoms, arthritis, and/or skin lesions. In adult-onset SAIDs, clinical manifestations are often less pronounced and differ from typical pediatric features. The incidence and prevalence of adult-onset SAIDs remain unknown due to variations in classification criteria and heterogeneous population samples.Our objectives were: (a) to estimate the incidence of adult-onset SAIDs in a well-defined population, (b) to describe their demographic and clinical features, and (c) to document associated genetic variants.

Methods: We included all patients diagnosed with SAIDs with onset in adulthood (≥16 years of age) from January 1st, 2000 to December 31st, 2024 in Cantabria, Northern Spain. Patients were classified according to Yamaguchi and/or Fautrel criteria for adult-onset Still disease (AOSD) and Eurofever/PRINTO classification criteria for the remaining SAIDs. Annual incidence rates were calculated as cases per 100,000 inhabitants.

Results: We included 45 patients (24 women/21 men; mean age: 45.2±16.4 years). The mean annual incidence was 0.32 cases per 100,000 inhabitants, and the prevalence was 7.6 cases per 100,000. Patients were classified into the following SAIDs (Figure): AOSD (n=26), Cryopyrin-Associated Periodic Syndromes (CAPS) (n=5), Syndrome of Undifferentiated Recurrent Fever (SURF) (n=3), Familial Mediterranean Fever (FMF) (n=4), Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne Syndrome (PAPA) (n=2), YAO Syndrome (n=2), VEXAS (n=2), Schnitzler Syndrome (n=1). The demographic and clinical features are summarized in Table.The most common manifestations were recurrent fever (88.9%), arthralgia/arthritis (88.9%), asthenia (82.2%), and rash (77.8%). The median time from symptom onset to diagnosis was 3 [1-24] months. Genetic variants were identified in the following genes: NLRP12 (n=3), NOD2 (n=2), NLRP3 (n=2), MEFV (n=4), CD2BP1 (n=2), UBA1 (n=2), WDR1 (n=1), TNFAIP3 (n=1), BTD (n=1), SCL40A1 (n=1), SLC29A3 (n=1), NLRC4 (n=1).

Conclusion: Over a 20-year period, the mean annual incidence of adult-onset SAIDs was 0.46 cases per 100,000 inhabitants, with a prevalence of 11 cases per 100,000 in a well-defined population in Northern Spain. A similar gender distribution was observed, with AOSD being the most common condition.

Supporting image 1Table. Demographic, clinical, and laboratory characteristics of 45 patients with adult-onset SAIDs

Supporting image 2Figure. Classification of 45 patients with adult-onset SAIDs.


Disclosures: C. Lasa Teja: None; L. Muñoz-Llopis: None; D. Prieto-Peña: None; I. Morante Bolado: None; J. Martín-Varillas: AbbVie, Pfizer, Lilly, Celgene, Janssen, and UCB Pharma, 5; N. Paz-Gandiaga: None; R. Blanco: AbbVie/Abbott, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, Merck/MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6.

To cite this abstract in AMA style:

Lasa Teja C, Muñoz-Llopis L, Prieto-Peña D, Morante Bolado I, Martín-Varillas J, Paz-Gandiaga N, Blanco R. Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/epidemiology-of-adult-onset-systemic-autoinflammatory-diseases-in-a-well-defined-population-from-northern-spain/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epidemiology-of-adult-onset-systemic-autoinflammatory-diseases-in-a-well-defined-population-from-northern-spain/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology